These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

37 related articles for article (PubMed ID: 31638158)

  • 21. The role of factor Xa inhibitors in venous thromboembolism treatment.
    Cabral KP; Ansell JE
    Vasc Health Risk Manag; 2015; 11():117-23. PubMed ID: 25673997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antithrombotic Agents.
    Chan NC; Weitz JI
    Circ Res; 2019 Feb; 124(3):426-436. PubMed ID: 30702990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticoagulation Therapy and NOACs in Heart Failure.
    Thomas I; EncisoSilva J; Schlueter M; Greenberg B
    Handb Exp Pharmacol; 2017; 243():515-535. PubMed ID: 28233177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rivaroxaban for prevention and treatment of venous thromboembolism.
    Chan NC; Weitz JI
    Future Cardiol; 2019 Mar; 15(2):63-77. PubMed ID: 30779598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies.
    Khorana AA; Weitz JI
    Thromb Haemost; 2018 May; 118(S 01):S23-S33. PubMed ID: 29566417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticoagulant and antiplatelet therapy in heart failure.
    Cleland JG
    Curr Opin Cardiol; 1997 May; 12(3):276-87. PubMed ID: 9243085
    [No Abstract]   [Full Text] [Related]  

  • 27. Atrial fibrillation, bleeding, and coronary intervention: current recommendations.
    Farhan S; Mehran R
    Coron Artery Dis; 2017 Dec; 28(8):702-709. PubMed ID: 28938240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quick reference guide to apixaban.
    Hurst KV; O'Callaghan JM; Handa A
    Vasc Health Risk Manag; 2017; 13():263-267. PubMed ID: 28744136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A look back: the quest for thrombosis in heart failure continues after COMMANDER HF.
    Filippatos G; Farmakis D
    Cardiovasc Res; 2019 Nov; 115(13):e140-e142. PubMed ID: 31638158
    [No Abstract]   [Full Text] [Related]  

  • 30. The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease.
    Camm AJ
    Thromb Haemost; 2018 May; 118(S 01):S2-S11. PubMed ID: 29566415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection?
    Bauersachs R; Zannad F
    Thromb Haemost; 2018 May; 118(S 01):S12-S22. PubMed ID: 29566413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
    Ajmal M; Friedman J; Sipra QUAR; Lassar T
    Cardiovasc Ther; 2021; 2021():8886210. PubMed ID: 33505518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticoagulation in Patients with Heart Failure and Sinus Rhythm.
    Li X; Yang J; Xu D
    Int Heart J; 2020 Nov; 61(6):1204-1211. PubMed ID: 33191346
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.